Whole-body tissue stabilization and selective extractions via tissue-hydrogel hybrids for high resolution intact circuit mapping and phenotyping
In various embodiments, the present application teaches methods for tissue clearing in which tissues are rendered macromolecule-permeable and optically-transparent, thereby exposing their cellular structure with intact connectivity. In some embodiments, the present application teaches ePACT, which is a protocol for enhanced tissue clearing via expansion. In some embodiments, the present application teaches visualizing a tissue that has been expanded via ePACT.
1. A method for clearing and expanding tissue, the method comprising the steps of:
(1) applying a fixing solution to the tissue, thereby forming fixed-tissue;
(2) applying a surfactant to the fixed-tissue, thereby forming permeabilized-tissue;
(3) incubating the permeabilized-tissue in a solution comprising acrylate-acrylamide copolymer (AcAm) and one or more polymerizing agent;
(4) incubating the tissue in a solution comprising sodium dodecyl sulfate (SDS), thereby forming SDS-treated cleared tissue;
(5) incubating the SDS-treated cleared tissue in a solution comprising 1-10 mg/mL collagenase or amounts between and for 1-48 hours, thereby forming collagenase-treated tissue; and
(6) incubating the collagenase-treated tissue in water, thereby forming cleared and expanded tissue.
2. The method of claim 1 , wherein the fixing solution is comprised of 1-15% paraformaldehyde (PFA) and/or 0.1-5% glutaraldehyde.
3. The method of claim 1 , further comprising applying a quenching solution to the fixed tissue.
4. The method of claim 3 , wherein the quenching solution comprises glycine.
5. The method of claim 1 , wherein the surfactant comprises Triton X-100.
6. The method of claim 1 , wherein the solution comprising surfactant further comprises phosphate buffered saline (PBS).
7. The method of claim 1 , wherein the solution comprising AcAm comprises 0-4% acrylamide, 4-10% sodium acrylate, and 0-1% bis-acrylamide.
8. The method of claim 1 , wherein the solution comprising SDS comprises SDS at a concentration of 4-10%.
9. The method of claim 1 , wherein the pH of the solution comprising SDS is 6.5-9.5.
10. The method of claim 1 , wherein the tissue comprises animal tissue.
11. The method of claim 10 , wherein the tissue comprises mammalian tissue.
12. The method of claim 11 , wherein the tissue comprises brain tissue.
13. The method of claim 1 , wherein the tissue is immunolabeled and/or fluorescently labeled.
14. The method of claim 1 , further comprising incubating the tissue in a refractive index matching solution (RIMS).
15. A method for visualizing and/or imaging a cleared and expanded tissue, comprising utilizing a microscope to visualize and/or image a tissue treated according to claim 1 .
16. The method of claim 15 , wherein the tissue comprises fluorescently labeled cells.
17. The method of claim 15 , wherein the refractive index of the tissue has been homogenized.
18. The method of claim 16 , further comprising counting the fluorescently labeled cells.
19. The method of claim 18 , wherein the fluorescently labeled cells are automatically counted.
20. The method of claim 15 , wherein one or more nucleic acids within the tissue are labeled with a marker that can be visualized and/or imaged with a microscope.
21. The method of claim 20 , wherein one or more of the nucleic acids is mRNA.
22. The method of claim 21 , wherein the one or more nucleic acids are labeled using single molecule fluorescence in-situ hybridization (smFISH).
23. The method of claim 22 , further comprising quantifying one or more species of mRNA in the tissue based on a unique fluorescent signature.
24. The method of claim 1 , wherein incubating the SDS-treated cleared tissue in a solution comprises a solution with greater than 2 mg/mL collagenase for more than 2 hours.
25. The method of claim 1 , wherein incubating the SDS-treated cleared tissue in a solution comprising about 10 mg/mL collagenase comprises incubation for at least 12-24 hours.
26. The method of claim 25 , wherein incubating the SDS-treated cleared tissue in a solution comprises incubation at less than 40° C.